M08.27
Juvenile rheumatoid arthritis with systemic onset, ankle and foot
Clinical Classification Guidelines
Medical Intelligence & Overview
Juvenile rheumatoid arthritis (JRA), also known as juvenile idiopathic arthritis, is a condition that causes inflammation in the joints of children and adolescents. The specific type identified by ICD-10 code M08.27 is systemic onset juvenile rheumatoid arthritis, which not only affects the joints—particularly the ankles and feet—but also involves systemic symptoms that can impact the whole body. These features set this form apart from other types of juvenile arthritis, resulting in a complex condition that requires careful management and monitoring.
Causes & Symptoms
Clinical Causes: The exact cause of juvenile rheumatoid arthritis with systemic onset remains unknown. It is believed to involve an abnormal immune response where the body's immune system mistakenly attacks its own tissues. Genetic factors may play a role, as a family history of autoimmune diseases can increase the risk. Environmental triggers, such as infections, could potentially contribute to the development of the condition, though these are not definitive causes.
Key Symptoms: Persistent joint swelling, particularly in the ankles and feet Fever that may come and go, often spiking in the late afternoon or evening Rash, which can be salmon-pink and appear on the torso or limbs Fatigue and general feeling of being unwell Muscle pain and stiffness, especially in the mornings Swelling and redness around the affected joints Loss of appetite and weight loss in some cases Enlargement of lymph nodes or the spleen in systemic cases
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of medical history, physical examination, and various tests. A doctor will assess symptoms and look for signs of systemic inflammation. Laboratory tests such as blood counts, markers of inflammation (like ESR and CRP), and autoimmune indicators (including rheumatoid factor and ANA) are used. Imaging studies, such as X-rays or ultrasounds, can evaluate joint damage or swelling. There is no single test for juvenile rheumatoid arthritis; diagnosis is based on overall clinical evaluation and ruling out other conditions.
Treatment Protocols: While there is no cure for juvenile rheumatoid arthritis, several treatment options aim to control symptoms, reduce inflammation, and prevent joint damage. Common approaches include: - **Nonsteroidal anti-inflammatory drugs (NSAIDs):** To reduce pain and swelling. - **Corticosteroids:** For managing severe symptoms or systemic involvement. - **Disease-modifying antirheumatic drugs (DMARDs):** Such as methotrexate, which slow disease progression. - **Biologic agents:** Targeted therapies that block specific components of the immune response. - **Physical therapy:** To maintain joint function and muscle strength. - **Regular monitoring:** Essential for adjusting treatments and managing potential side effects. Psychosocial support and patient education are also important elements of comprehensive care, helping children and their families cope with the disease and its impact on daily life.
Clinical Advice & FAQs
Billing Guidance
Is M08.27 a billable ICD-10 code?
Yes, M08.27 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M08.27?
Clinical documentation must specify the nature of Juvenile rheumatoid arthritis with systemic onset, ankle and foot and any associated comorbidities for accurate reporting.
Cite this Clinical Reference